Latest News

Chicago, Illinois – A new antibiotic that works by disrupting two different cellular targets would make it 100 million times more difficult for bacteria to evolve resistance, according to new research from the University of Illinois Chicago. For a new paper in Nature Chemical Biology, researchers probed how a class of synthetic...
SAN FRANCISCO, Calif. — Acelot, a biotechnology company developing small molecule therapies for challenging targets in diseases with high unmet need, today announced the initiation of the Phase Ia clinical trial of ACE-2223 to evaluate its safety, tolerability, and pharmacokinetics in healthy adults. The first-in-class, orally bioavailable small molecule, ACE-2223,...
IRVING, Texas -Acentrus Specialty™, a national network of health systems and hospitals committed to providing specialty pharmacy care for their patients, has finalized an agreement with Chiasma, Inc. (NASDAQ: CHMA) to provide qualified Acentrus clients access to MYCAPSSA® (octreotide), delayed-release oral capsules for long-term maintenance treatment in acromegaly patients who...